pharma · Osteoarthritis of Knee
KeyZell
Amzell
Amzell is a pharma organization headquartered in CN. Primary therapeutic focus areas include Osteoarthritis of Knee. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity fr
ES HQ
11 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- ES
- Employees
- 11
- Programs
- 1
- Drugs
- 1
- Patents
- 0
AMZ001 Diclofenac gel
Phase 3 · small molecule · Osteoarthritis of Knee
AMZ001 Diclofenac gel for Osteoarthritis of Knee is a Phase 3 program (small_molecule) at Amzell with 1 ClinicalTrials.gov record(s).
Internal code AMZ001-007
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Amzell
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Osteoarthritis of Knee
- Status
- completed
- Trials
- 1